Theravance Biopharma
TBPH
About: Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Employees: 97
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
69% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 32
67% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 5 (+2) [Q2]
28% more capital invested
Capital invested by funds: $401M [Q1] → $512M (+$111M) [Q2]
20% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 20
3% more funds holding
Funds holding: 131 [Q1] → 135 (+4) [Q2]
2.12% more ownership
Funds ownership: 90.75% [Q1] → 92.87% (+2.12%) [Q2]
99% less call options, than puts
Call options by funds: $3K | Put options by funds: $286K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
B. Riley Securities
Mayank Mamtani
|
$28
|
Buy
Initiated
|
12 Sep 2025 |
|
BTIG
Julian Harrison
|
$25
|
Buy
Maintained
|
27 Jun 2025 |
|
Jones Trading
Debanjana Chatterjee
|
$24
|
Buy
Initiated
|
17 Jun 2025 |
Financial journalist opinion
Based on 3 articles about TBPH published over the past 30 days
